{"analyses":[{"ciLowerLimit":"0.601","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.100","groupDescription":"All analyses based on final database lock (DBL) were descriptive only with p-values reported as nominal.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1782","paramType":"Hazard Ratio (HR)","paramValue":"0.813","statisticalMethod":"Stratified Log Rank"},{"ciLowerLimit":"0.472","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.874","groupDescription":"All analyses based on final DBL were descriptive only.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.642"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.7","upperLimit":"24.2","value":"15.9"},{"groupId":"OG001","lowerLimit":"13.7","upperLimit":"28.3","value":"20.1"},{"groupId":"OG002","lowerLimit":"10.0","upperLimit":"17.7","value":"13.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Part 1 participants only","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 82.2 months","title":"Part 1: Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}